Evaluation of the Charlson comorbidity index to predict early mortality in implantable cardioverter defibrillator patients

Annals of Noninvasive Electrocardiology

Volumn 18, Issue 4, 2013, Pages 379-388

  Bhavnani, Sanjeev P ^a   Coleman, Craig I ^a   Guertin, Danette ^a   Yarlagadda, Ravi K ^a   Clyne, Christopher A ^a   Kluger, Jeffrey ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

comorbidities; implantable cardioverter defibrillator; mortality; outcomes; risk stratification; shocks

Indexed keywords

ADULT; AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONFIDENCE INTERVAL; EVALUATION; FEMALE; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SHOCK; SUDDEN CARDIAC DEATH;

COMORBIDITIES; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MORTALITY; OUTCOMES; RISK STRATIFICATION; SHOCKS;

AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; CAUSE OF DEATH; COHORT STUDIES; COMORBIDITY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; KAPLAN-MEIER ESTIMATE; LIFE EXPECTANCY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880809891     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/anec.12045     Document Type: Article

References (35)

1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 3: 225-237.
2. The Antiarrhythmic versus Implantable Cardioverter Defibrillators Investigators. A comparison of antiarrhythmic-drug therapy with implantable cardioverter defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583.
3. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
4. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.
5. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350: 2151-2158.
6. Hammill SC, Kremers MS, Stevenson LW, et al. Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm 2010; 9: 1340-1345.
7. Hernandez AF, Fonarow GC, Liang L, et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 2007; 298: 1525-1532.
8. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation 2008; 117: e350-408.
9. Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death. Circulation 2008; 118: 1497-1518.
10. Köbe J, Eckardt L,. Early mortality in implantable cardioverter defibrillator patients: From randomized controlled trials to real life. Europace 2009; 11: 694-696.
11. Kramer DB, Friedman PA, Kallinen LM, et al. Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators. Heart Rhythm 2012; 9: 42-46.
12. Koller MT, Schaer B, Wolbers M, et al. Death without prior appropriate implantable cardioverter defibrillator therapy: A competing risk study. Circulation 2008; 117: 1918-1926.
13. Stein KM, Mittal S, Gilliam FR, et al. Predictors of early mortality in implantable cardioverter-defibrillator recipients. Europace 2009; 11: 734-760.
14. Epstein AE, Kay GN, Plumb VJ, et al. Implantable cardioverter- defibrillator prescription in the elderly. Heart Rhythm 2009; 6: 1136-1143.
15. Aggarwal A, Wang Y, Rumsfeld JS, et al. National Cardiovascular Data Registry. Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation. Heart Rhythm 2009; 6: 1561-1571.
16. Fishman GI, Chugh SS, Dimarco JP, et al. Sudden cardiac death prediction and prevention: Report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010; 30: 2335-2348.
17. von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573-577.
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies. J Chron Dis 1987; 40: 373-383.
19. Sachdev M, Sun JL, Tsiatis AA, et al. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol 2004; 43: 576-582.
20. Lee DS, Tu JV, Austin PC, et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 2007; 49: 2408-2415.
21. Swindle JP, Rich MW, McCann P, et al. Implantable cardiac devices procedures in older patients. Arch Intern Med 2010; 170: 631-637.
22. Gleva MJ, Holcomb R, Uslan D, et al. Charlson comorbidity index and risk of cardiac rhythm device generator replacement: Results from the REPLACE Registry. Circulation 2009; 120: S637.
23. Levy WC, Lee KL, Hellkamp AS, et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009; 120: 835-842.
24. Buxton AE, Lee KL, Hafley GE, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: Lessons from the MUSTT study. J Am Coll Cardiol 2007; 50: 1150-1157.
25. Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008; 22: 288-296.
26. Cleland JG,. CARE-HF long-term follow-up effect of CRT on all-cause mortality. Presented at the European Society of Cardiology 2010 Congress, Stockholm, Sweden, September 3, 2010.
27. Saxon LA, Bristow MR, Boehmer J, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure Trial. Circulation 2006; 114: 2766-2772.
28. Barsheshet A, Goldenberg I, Narins CR, et al. Time dependence of life-threatening ventricular tachyarrhythmias after coronary revascularization in MADIT-CRT. Heart Rhythm 2010; 7: 1421-1427.
29. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA 2003; 20: 2685-2694.
30. Bhavnani SP, Kluger J, Coleman CI, et al. The prognostic impact of shocks for clinical and induced arrhythmias on morbidity and mortality among patients with implantable cardioverter-defibrillators. Heart Rhythm 2010; 7: 755-760.
31. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329-1338.
32. Dickstein K, Vardas PE, Auricchio A, et al. Focused Update of ESC guidelines on device therapy in heart failure: An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Eur Heart J 2010; 12: 1143-1153.
33. Al-Khatib SM, Hellkamp A, Curtis J, et al. Non-evidence-based ICD implantations in the United States. JAMA 2011; 305: 43-49.
34. Fein AS, Wang Y, Curtis JP, et al. Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the NCDR-ICD registry. J Am Coll Cardiol 2010; 56: 766-773.
35. Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010; 55: 2769-2777.